|
1.
|
|
15 p, 3.7 MB |
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
/
Botta, Cirino (Clínica Universidad de Navarra) ;
Perez, Cristina (Clínica Universidad de Navarra) ;
Larrayoz, Marta (Clínica Universidad de Navarra) ;
Puig, Noemí (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre) ;
Termini, Rosalinda (Clínica Universidad de Navarra) ;
Goicoechea, Ibai (Clínica Universidad de Navarra) ;
Rodriguez, Sara (Clínica Universidad de Navarra) ;
Zabaleta, Aintzane (Clínica Universidad de Navarra) ;
Lopez, Aitziber (Clínica Universidad de Navarra) ;
Sarvide, Sarai (Clínica Universidad de Navarra) ;
Blanco, Laura (Clínica Universidad de Navarra) ;
Papetti, Daniele Marco (Department of Informatics. University of Milano-Bicocca) ;
Nobile, M.S. (Biostatistics and Bioimaging Centre-B4) ;
Besozzi, Daniela (Biostatistics and Bioimaging Centre-B4) ;
Gentile, Massimo (Department of Oncohematology. "Annunziata" Hospital) ;
Correale, Pierpaolo (Great Metropolitan Hospital "Riuniti" of Reggio Calabria) ;
Siragusa, Sergio (Department of Health Promotion. University of Palermo) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Garcia, Maria Esther (Hospital Universitario de Cabueñes (Gijón)) ;
Sureda, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
de Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ;
Ríos-Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Moraleda, José María (Instituto Murciano de Investigación Biosanitaria) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Hernández, Miguel T. (Hospital Universitario de Canarias (Illes Canàries)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Illes Balears)) ;
Palomera, Luís (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Pérez-Montaña, Albert (Hospital Universitari Son Espases (Illes Balears)) ;
Goldschmidt, Hartmut (Department of Internal Medicine V. University of Heidelberg) ;
Avet-Loiseau, Hervé (IUC-T Oncopole) ;
Roccaro, Aldo (Department of Hematology. ASST Spedali Civili di Brescia) ;
Orfao, Alberto (Universidad de Salamanca. Departament de Medicina) ;
Martinez-Lopez, Joaquín (Hospital Universitario 12 de Octubre) ;
Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mateos, M. V (Hospital Universitario de SalamancaBiomedica de Salamanca (IBSAL). Centro de Investigación del Cancer (IBMCC-USAL. CSIC)) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Martinez Climent, Juan-José (Clínica Universidad de Navarra) ;
Paiva, Bruno (Clínica Universidad de Navarra)
Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). [...]
2023 -  10.1038/s41467-023-41562-6
Nature communications, Vol. 14 Núm. 1 (december 2023) , p. 5825
|
|
|
2.
|
|
8 p, 1.0 MB |
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
/
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ;
Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K (Winship Cancer Institute. Emory University) ;
Martin, Thomas (University of California San Francisco) ;
Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud) ;
Benboubker, Lotfi (Hôpital Bretonneau) ;
Mateos, Maria-Victoria (University Hospital de Salamanca) ;
Popat, Rakesh (University College London Hospitals) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Sidana, Surbhi (Stanford University of Medicine) ;
Delforge, Michele (University of Leuven) ;
Pei, Lixia (Janssen Research & Development) ;
Trancucci, Danielle (Janssen Research & Development) ;
Olyslager, Yunsi (Janssen Research & Development) ;
Uhlar, Clarissa (Janssen Research & Development) ;
Stephenson, Tara (Janssen Research & Development) ;
Rampelbergh, Rian Van (Janssen Research & Development) ;
Banerjee, Arnob (Janssen Research & Development) ;
Kobos, Rachel (Janssen Research & Development) ;
Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818
|
|
|
3.
|
|
9 p, 603.3 KB |
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study
/
Martin, Thomas G. (University of California San Francisco, USA) ;
Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France) ;
Usmani, Saad Z. (Levine Cancer Institute/Atrium Health, Charlotte, NC) ;
Garfall, Alfred (University of Pennsylvania, Philadelphia, PA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
San-Miguel, Jesús F. (Clínica Universidad de Navarra) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K. (Emory University, Atlanta, GA) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Chari, Ajay (Mount Sinai School of Medicine, New York, USA) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud, Pierre-Bénite, France) ;
Krishnan, Amrita (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ;
Bahlis, Nizar (University of Calgary, Canada) ;
Popat, Rakesh (University College London) ;
Besemer, Britta (University of Tuebingen, Tuebingen, Germany) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Delforge, Michel (Universitaire Ziekenhuizen Leuven, Belgium) ;
Trancucci, Danielle (Janssen Research & Development, Raritan, NJ) ;
Pei, Lixia (Janssen Research & Development, Raritan, NJ) ;
Kobos, Rachel (Janssen Research & Development, Raritan, NJ) ;
Fastenau, John (Janssen Research & Development, Raritan, NJ) ;
Gries, Katharine S. (Janssen Research & Development, Raritan, NJ) ;
van de Donk, Niels W.C.J. (Amsterdam University Medical Center, Vrije Universiteit Amsterdam, The Netherlands)
Introduction: Patients with relapsed or refractory multiple myeloma (RRMM) report significantly lower HRQoL compared with patients with newly diagnosed MM and experience further deterioration in HRQoL with each relapse and subsequent treatment. [...]
2023 - 10.1016/j.clml.2023.11.001
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
4.
|
|
4 p, 756.5 KB |
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS
/
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Haenel, M. (Klinikum Chemnitz, Germany) ;
Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ;
Ailawadhi, Sikander (Mayo Clinic Florida, USA) ;
Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ;
de la Rubia Comos, Javier (Catholic University of Valencia) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ;
Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ;
Terebelo, Howard (Providence Cancer Center, Southfield, USA) ;
Yang, Shiyi (Janssen Research & Development. LLC, USA) ;
Wang, Jianping (Janssen Research & Development. LLC, USA) ;
Nnane, Ivo (Janssen Research & Development. LLC, USA) ;
Qi, Ming (Janssen Research & Development. LLC, USA) ;
Kosh, Michele (Janssen Research & Development. LLC, USA) ;
Delioukina, Maria (Janssen Research & Development. LLC, USA) ;
Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)
|
|
|
5.
|
|
14 p, 1.7 MB |
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
/
López-Anglada, Lucía (Hospital 12 de Octubre (Madrid)) ;
Cueto-Felgueroso, Cecilia (Hospital 12 de Octubre (Madrid)) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teruel, Ana Isabel (Hospital Clínic Universitari (València)) ;
Lopez de la Guia, Ana (Hospital Universitario La Paz (Madrid)) ;
Bengoechea, Enrique (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Palomera, Luis (Hospital Clínico Universitario Lozano Blesa) ;
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Hernandez, Jose Mariano (Hospital General de Segovia) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Peñalver, Francisco Javier (Hospital Universitario Fundacion Alcorcon) ;
García-Sanz, Ramón (Hospital Universitario de Salamanca-IBSAL) ;
Besalduch, Juan (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Gonzalez Montes, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta) ;
Martinez, Rafael Benigno (Hospital Universitario Clínico San Carlos (Madrid)) ;
Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Gutierrez, Norma C. (Hospital Clínic i Provincial de Barcelona) ;
Puerta, Paloma (Hospital 12 de Octubre (Madrid)) ;
Valeri, Antonio (Hospital 12 de Octubre (Madrid)) ;
Paiva, Bruno (Clínica Universidad de Navarra) ;
Bladé Creixenti, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mateos, Maria-Victoria (Hospital Clínic i Provincial de Barcelona) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Lahuerta, J. J. (Hospital Universitario 12 de Octubre (Madrid)) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. [...]
2018 - 10.1371/journal.pone.0203392
PloS one, Vol. 13 Núm. 9 (september 2018) , p. e0203392
|
|
|
6.
|
|
9 p, 1.7 MB |
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
/
Onecha, Esther (Centro Nacional de Investigaciones Oncológicas) ;
Linares, Maria (Centro Nacional de Investigaciones Oncológicas) ;
Rapado, Inmaculada (Centro de Investigación Biomédica en Red de Cáncer) ;
Ruiz-Heredia, Yanira (Centro Nacional de Investigaciones Oncológicas) ;
Martinez-Sanchez, Pilar (Hospital 12 de Octubre (Madrid)) ;
Cedena, Teresa (Centro Nacional de Investigaciones Oncológicas) ;
Pratcorona, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Oteyza, Jaime Perez (Hospital Universitario HM Sanchinarro (Madrid)) ;
Herrera, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Barragán, Eva (Hospital Universitari i Politècnic La Fe (València)) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Vela, Jose Antonio Garcia (Hospital Universitario de Getafe (Madrid)) ;
Magro, Elena (Hospital Universitario Príncipe de Asturias (Alcalá de Henares, Madrid)) ;
Anguita, Eduardo (Hospital Clínico San Carlos (Madrid)) ;
Figuera, Angela (Hospital Universitario de la Princesa (Madrid)) ;
Riaza, Rosalia (Hospital Universitario Severo Ochoa) ;
Martinez-Barranco, Pilar (Hospital Universitario Fundación Alcorcón) ;
Sanchez-Vega, Beatriz (Centro Nacional de Investigaciones Oncológicas) ;
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Gallardo, Miguel (Centro Nacional de Investigaciones Oncológicas) ;
Martinez-Lopez, Joaquin (Centro Nacional de Investigaciones Oncológicas) ;
Ayala, Rosa (Centro Nacional de Investigaciones Oncológicas) ;
Universitat Autònoma de Barcelona
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. [...]
2019 - 10.3324/haematol.2018.194712
Haematologica, Vol. 104 Núm. 2 (31 2019) , p. 288-296
|
|
|
7.
|
|
12 p, 2.2 MB |
Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain
/
Arenaza, Ainhoa (Clínico San Carlos Hospital) ;
Diez, Raúl (Hospital Universitario de Getafe (Madrid)) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Di Nicolantonio, Roberta (Novartis Farmacéutica S.A) ;
Gostkorzewicz, Joana (Novartis Farmacéutica S.A) ;
Martínez, Carlos (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Martínez Llinàs, Diana (Oblikue Consulting. S.L) ;
Martínez-López, Joaquín (Hospital 12 de Octubre (Madrid)) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Moure-Fernández, Aída (Oblikue Consulting. S.L) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Vinent, Joan Lluís (Hospital Sant Joan de Déu (Manresa)) ;
Universitat Autònoma de Barcelona
The addition of midostaurin to standard chemotherapy (cytarabine and daunorubicin) has shown significant improvements in the survival of patients with acute myeloid leukemia with the FLT3 mutation (FLT3-AML). [...]
2019 - 10.2147/CEOR.S222879
ClinicoEconomics and outcomes research, Vol. 11 (2019) , p. 683-694
|
|
|
8.
|
|
8 p, 1.1 MB |
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
/
Encinas, Cristina (Hospital General Universitario Gregorio Marañón (HGUGM). IiSGM) ;
Hernandez-Rivas, José-Ángel (Hospital Universitario Infanta Leonor) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona. CIBERONC) ;
Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
Bellón, José-María (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
García-Sanz, Ramón (Hospital Universitario de Salamanca (IBSAL). CIBERONC e Instituto de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC)) ;
de la Rubia, Javier (Hospital Universitari Doctor Peset (València)) ;
López de la Guía, Ana (Hospital Universitario La Paz (Madrid)) ;
Jímenez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ;
Jarque, Isidro (Hospital Universitario la Fe. CIBERONC) ;
Iñigo, Belén (Hospital Clínico San Carlos (Madrid)) ;
Dourdil, Victoria (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Cuéllar Pérez-Ávila, Clara (Hospital Universitario 12 de Octubre (Madrid)) ;
Gonzalez, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta) ;
Hernández, Miguel-Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Otero, Paula (Clínica Universitaria de Navarra. CIMA. IDISNA. CIBERONC) ;
Silvent, Maialen (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Cabrera, Carmen (Complejo Hospitalario de Cáceres) ;
Rios, Rafael (Hospital Universitario Virgen de las Nieves (Granada)) ;
Alegre, Adrián (Hospital Universitario de la Princesa. Hospital Universitario Quirónsalud) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Gonzalez, Marta-Sonia (Hospital Universitario de Santiago) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Ocio, Enrique M. (Hospital Universitario Marqués de Valdecilla. (IDIVAL). Universidad de Cantabria) ;
Krsnik, Isabel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
García, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
García-Mateo, Aránzazu (Hospital General de Segovia) ;
Soler, Joan-Alfons (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Martín Sánchez, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Arguiñano, José M (Complejo Hospitalario de Navarra) ;
Mateos, M. V. (Instituto de Investigación Biomédica de Salamanca) ;
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona. CIBERONC) ;
San-Miguel, J (Clínica Universitaria de Navarra. CIMA. IDISNA; CIBERONC) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre (Madrid)) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. [...]
2022 - 10.1038/s41408-022-00652-2
Blood Cancer Journal, Vol. 12 Núm. 4 (april 2022) , p. 68
|
|
|
9.
|
|
1 p, 825.9 KB |
Correction : Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
/
Mansouri, Larry (Karolinska Institutet (Estocolm, Suècia)) ;
Thorvaldsdottir, Birna (Karolinska Institutet (Estocolm, Suècia). Department of Molecular Medicine and Surgery) ;
Sutton, Lesley-Ann (Karolinska Institutet (Estocolm, Suècia)) ;
Karakatsoulis, Georgios (University of Ioannina) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Parker, Helen (University of Southampton) ;
Nadeu, Ferran (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Brieghel, Christian (Copenhagen University Hospital) ;
Laidou, Stamatia (Institute of Applied Biosciences) ;
Moia, Riccardo (Università del Piemonte Orientale) ;
Rossi, Davide (Institute of Oncology Research) ;
Catherwood, Mark (Queen's University Belfast) ;
Kotaskova, Jana (Masaryk University) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez-Vicente, Ana E. (Universidad de Salamanca) ;
Benito, Rocío (Universidad de Salamanca) ;
Rigolin, Gian Matteo (University of Ferrara) ;
Bonfiglio, Silvia (Università Vita Salute San Raffaele) ;
Scarfo, Lydia (Università Vita Salute San Raffaele) ;
Mattsson, Mattias (Uppsala University) ;
Davis, Zadie (University Hospitals Dorset) ;
Gogia, Ajay (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Rani, Lata (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Baliakas, Panagiotis (Uppsala University) ;
Foroughi-Asl, Hassan (Karolinska Institutet (Estocolm, Suècia)) ;
Jylhä, Cecilia (Karolinska Institutet (Estocolm, Suècia)) ;
Skaftason, Aron (Karolinska Institutet (Estocolm, Suècia)) ;
Rapado, Inmaculada (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Miras, Fatima (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Lopez, Joaquín (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
de la Serna, Javier (Centro Nacional de Investigaciones Oncológicas Carlos III (Espanya)) ;
Rivas, Jesús María Hernández (Universidad de Salamanca) ;
Thornton, Patrick (Beaumont Hospital (Dublín, Irlanda)) ;
Larráyoz, María José (Universidad de Navarra) ;
Calasanz, M.J (Universidad de Navarra) ;
Fésüs, Viktória (Semmelweis University) ;
Mátrai, Zoltán (Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases (Budapest, Hongria)) ;
Bödör, Csaba (Semmelweis University) ;
Smedby, Karin E. (Karolinska Institutet (Estocolm, Suècia)) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gupta, Ritu (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Bárbara (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Baran-Marszak, Fanny (Hôpital Avicenne AP-HP) ;
Oscier, David (University Hospitals Dorset) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Zenz, Thorsten (University Hospital of Zurich) ;
Terol, Maria Jose (Universitat de València) ;
Cuneo, Antonio (University of Ferrara) ;
Hernández-Sánchez, María (Universidad de Salamanca) ;
Pospisilova, Sarka (Masaryk University) ;
Mills, Ken (Queen's University Belfast) ;
Gaidano, Gianluca (Università del Piemonte Orientale) ;
Niemann, Carsten U. (Copenhagen University Hospital) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Strefford, Jonathan C. (University of Southampton) ;
Ghia, Paolo (Università Vita Salute San Raffaele) ;
Stamatopoulos, Kostas (Institute of Applied Biosciences) ;
Rosenquist, Richard (Karolinska University Hospital and Karolinska Institutet (Suècia))
2023 - 10.1038/s41375-023-01813-3
Leukemia, Vol. 37 (january 2023) , p. 504
|
|
|
10.
|
|
9 p, 1.7 MB |
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status : a study by ERIC in HARMONY
/
Mansouri, Larry (Karolinska Institutet (Estocolm, Suècia)) ;
Thorvaldsdottir, Birna (Karolinska Institutet (Estocolm, Suècia)) ;
Sutton, Lesley-Ann (Karolinska Institutet (Estocolm, Suècia)) ;
Karakatsoulis, Georgios (University of Ioannina. Department of Mathematics) ;
Meggendorfer, Manja (MLL Munich Leukemia Laboratory) ;
Parker, Helen (University of Southampton) ;
Nadeu, Ferran (Centro de Investigación Biomédica en Red de Cáncer) ;
Brieghel, Christian (Copenhagen University Hospital. Department of Hematology, Rigshospitalet) ;
Laidou, Stamatia (Centre for Research and Technology Hellas (Tessalònica, Grècia)) ;
Moia, Riccardo (Università del Piemonte Orientale) ;
Rossi, Davide (Institute of Oncology Research (Suïssa)) ;
Catherwood, Mark (Queen's University Belfast) ;
Kotaskova, Jana (Masaryk University) ;
Delgado, Julio (Universitat de Barcelona) ;
Rodríguez-Vicente, Ana E. (Hospital Universitario de Salamanca) ;
Benito, Rocío (Hospital Universitario de Salamanca) ;
Rigolin, Gian Matteo (University of Ferrara) ;
Bonfiglio, Silvia (Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Scarfo, Lydia (Università Vita Salute San Raffaele) ;
Mattsson, Mattias (Uppsala University. Department of Immunology, Genetics and Pathology) ;
Davis, Zadie (Molecular Pathology Department, University Hospitals Dorset) ;
Gogia, Ajay (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Rani, Lata (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Baliakas, Panagiotis (Uppsala University. Department of Immunology, Genetics and Pathology) ;
Foroughi-Asl, Hassan (Karolinska Institutet (Estocolm, Suècia)) ;
Jylhä, Cecilia (Karolinska Institutet (Estocolm, Suècia)) ;
Skaftason, Aron (Karolinska Institutet (Estocolm, Suècia)) ;
Rapado, Inmaculada (Spanish National Cancer Research) ;
Miras, Fatima (Hospital Universitario 12 de Octubre (Madrid)) ;
Martinez-Lopez, Joaquín (Spanish National Cancer Research) ;
de la Serna, Javier (Spanish National Cancer Research) ;
Rivas, Jesús María Hernández (Hospital Universitario de Salamanca) ;
Thornton, Patrick (Beaumont Hospital. Haematology Department) ;
Larráyoz, María José (Instituto de Investigación Sanitaria de Navarra) ;
Calasanz, M.J (Instituto de Investigación Sanitaria de Navarra) ;
Fésüs, Viktória (Semmelweis University) ;
Mátrai, Zoltán (Central Hospital of Southern Pest-National Institute of Hematology and Infectious Diseases, Budapest, Hungary) ;
Bödör, Csaba (Semmelweis University) ;
Smedby, Karin E. (Karolinska Institutet (Suècia). Department of Medicine Solna) ;
Espinet, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gupta, Ritu (All India Institute of Medical Sciences (Nova Delhi, Índia)) ;
Bullinger, Lars (Charité - Universitätsmedizin Berlin) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Tazón-Vega, Bárbara (Vall d'Hebron Institut d'Oncologia) ;
Baran-Marszak, Fanny (Service d'hématologie Biologique Hôpital Avicenne Assistance Publique des Hôpitaux de Paris) ;
Oscier, David (University Hospitals Dorset) ;
Nguyen-Khac, Florence (Sorbonne University) ;
Zenz, Thorsten (University Hospital and University of Zurich. Department of Oncology and Haematology) ;
Terol, Maria Jose (University of Valencia. Department of Hematology) ;
Cuneo, Antonio (University of Ferrara. Hematology-Department of Medical Sciences) ;
Hernández-Sánchez, María (Hospital Universitario de Salamanca) ;
Pospisilova, Sarka (Masaryk University. Central European Institute of Technology) ;
Mills, Ken (Queen's University Belfast) ;
Gaidano, Gianluca (Università del Piemonte Orientale) ;
Niemann, Carsten U. (Copenhagen University Hospital) ;
Campo, Elias (Universitat de Barcelona) ;
Strefford, Jonathan C. (University of Southampton) ;
Ghia, Paolo (Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele) ;
Stamatopoulos, Kostas (Institute of Applied Biosciences (Grècia)) ;
Rosenquist, Richard (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Universitat Autònoma de Barcelona
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status. [...]
2022 - 10.1038/s41375-022-01802-y
Leukemia, Vol. 37 (december 2022) , p. 339-347
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
